LCM
OPTR

LionEye Capital Management’s OPTIMER PHARMACEUTICALS, INC. COM STK OPTR Stock Holding History

LionEye Capital Management’s Portfolio OPTR Stock Details OPTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-177,799
Closed -$2.57M – 85
2013
Q2 		$2.57M Buy
+177,799
New +$2.59M 0.72% 45

Other funds holding OPTR

WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAA
Alpine Associates Advisors Englewood Cliffs, New Jersey $158M AUM 48.85% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

LionEye Capital Management's OPTR Position: Q3 2013 in Review

LionEye Capital Management sold out of OPTIMER PHARMACEUTICALS, INC. COM STK (OPTR) in Q3 2013, closing a stake of 177,799 shares — an estimated $2.57M sold.

LionEye Capital Management first reported a position in OPTR in Q2 2013 and held it in 1 quarter. The position peaked at $2.57M in Q2 2013. 104 funds tracked by Wall St. Rank hold OPTR as of Q3 2013.

  • LionEye Capital Management reported no remaining OPTIMER PHARMACEUTICALS, INC. COM STK position as of Q3 2013 after selling out during the quarter.
  • LionEye Capital Management sold 177,799 OPTIMER PHARMACEUTICALS, INC. COM STK shares in Q3 2013, an estimated $2.57M.
  • LionEye Capital Management first reported a position in OPTIMER PHARMACEUTICALS, INC. COM STK in Q2 2013 and held it in 1 quarter.
  • LionEye Capital Management's OPTIMER PHARMACEUTICALS, INC. COM STK position peaked at $2.57M in Q2 2013.
  • 104 funds tracked by Wall St. Rank held OPTIMER PHARMACEUTICALS, INC. COM STK as of Q3 2013.

Based on LionEye Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.